REGENXBIO (RGNX) and Nippon Shinyaku said Tuesday that they have formed a partnership for the development and commercialization of RGX-121 as a potential treatment for Hunter syndrome and RGX-111 for Hurler syndrome.
Under the terms of the deal, REGENXBIO will receive $110 million at closing and up to $700 million in additional payments if certain milestones are achieved, the companies said.
The payments include $40 million in potential development and regulatory milestones and $660 million in potential sales milestones, the companies said.
Additionally, REGENXBIO will also receive double-digit royalties on net sales in the US and Asia, the companies said.
Nippon Shinyaku will commercialize both products in the US and Asia while future clinical development of RGX-121 and RGX-111 will be led by REGENXBIO, the companies said.
Both Hunter's and Hurler's disease are rare genetic disorders leading to skeletal deformities and mental stagnation.
Shares of REGENXBIO rose more than 24% in Tuesday's premarket activity.
Price: 8.64, Change: +1.69, Percent Change: +24.32
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。